Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 14/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 6/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358254 | 1.00 | RIPK2 (1.00) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL29638044 | 1.00 | RIPK2 (1.00) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL2588852 | 0.89 | RIPK2 (0.80) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL2595172 | 0.88 | RIPK2 (1.00) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL12180824 | 0.88 | RIPK2 (0.78) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL2589216 | 0.87 | RIPK2 (0.77) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL2591634 | 0.86 | RIPK2 (0.80) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL2589400 | 0.85 | RIPK2 (0.79) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL2592429 | 0.85 | RIPK2 (0.79) | RIPK2RIPK3RIPK1KDREGFR | |
| SCHEMBL14718085 | 0.85 | RIPK2 (0.74) | RIPK2RIPK3RIPK1KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119185311-B | Application of GSK-872 in preparation of medicament for treating traumatic optic neuropathy | 汕头大学·香港中文大学联合汕头国际眼科中心 | 2025-02-07 | — | — | CN | claimed |
| CN-119185311-A | Application of GSK-872 in preparation of medicament for treating traumatic optic neuropathy | 汕头大学·香港中文大学联合汕头国际眼科中心 | 2024-12-27 | — | — | CN | claimed |
| CN-118924752-A | Use of RIP3 inhibitors for the preparation of pharmaceutical compositions for reducing ischemia reperfusion injury in lung transplantation | 浙江大学 | 2024-11-12 | — | — | CN | claimed |
| US-12117455-B2 | Early detection marker for degenerative osteoarthritis with TRIM24-RIP3 axis | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2024-10-15 | — | — | US | claimed |
| CN-118421664-A | Luciferase fluorescence complementary system for detecting programmed cell necrosis and construction method and application thereof | 宁夏医科大学 | 2024-08-02 | — | — | CN | claimed |
| CN-118416230-A | Inhibitors of RIPK3 and application thereof in preparation of osteoporosis and/or osteolysis treatment drugs | 苏州系统医学研究所 | 2024-08-02 | — | — | CN | claimed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-20240043809-A1 | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | NEW YORK UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| CN-117230097-A | Double-molecule fluorescent fragment complementary system for detecting programmed cell necrosis and construction method and application thereof | 同济大学 | 2023-12-15 | — | — | CN | claimed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| CN-115778955-A | Small molecule inhibitor for reducing glioblastoma immune suppression microenvironment and application thereof | 中国科学技术大学 | 2023-03-14 | — | — | CN | claimed |
| CN-115197913-A | Primary corneal endothelial cell culture solution and application thereof | 江苏齐氏生物科技有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-113616654-B | Application of GSK872 in preparation of medicines for treating diseases caused by enterovirus 71 infection | 广州市妇女儿童医疗中心 | 2022-08-12 | — | — | CN | claimed |
| CN-114586768-A | Liver tissue preservation solution and preservation method and application thereof | 江苏齐氏生物科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| CN-113648310-A | Application of GSK872 in preparation of medicine for treating nerve cell injury after cerebral hemorrhage | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 2021-11-16 | — | — | CN | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | claimed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK2 5/4885RIPK3 1/4885RIPK1 2/4885 |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | RIPK2 326/4885RIPK3 421/4885RIPK1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.